Treatment in the MAINTAIN Nephritis Trial Cohort at 10 years of follow-up*
| All (n=87) | MMF group (n=42) | AZA group (n=45) | p Value† | |
|---|---|---|---|---|
| Follow-up (months; median/range) | 110/18–156 | 105/18–156 | 114/18–152 | 0.80 |
| Age at follow-up (years; median/range) | 42±10 | 42±9 | 42±10 | 0.84 |
| Currently on GC (%) | 56 | 57 | 55 | 0.83 |
| Mean prednisolone daily dose (mg)‡ | 7.0±6.2 | 6.6±4.5 | 7.3±7.6 | 0.68 |
| Currently on IS (%) | 56 | 55 | 58 | 0.83 |
| Currently on AZA (%) | 24 | 14 | 33 | 0.047 |
| Currently on MMF (%) | 27 | 36 | 20 | 0.15 |
| Currently on BPLD (%) | 65 | 74 | 58 | 0.18 |
| Need for additional IS therapy (%) | 41 | 36 | 47 | 0.38 |
| Need for additional intravenous CY (>3 g) (%) | 19 | 14 | 20§ | 0.57 |
| Need for RTX (%) | 11 | 12 | 11 | >0.99 |
*Data on patients alive and not lost to follow-up.
†By unpaired t test or Fisher's exact test.
‡Calculated for patients on GC only.
§One AZA patient received additional intravenous CY for a neuropsychiatric non-renal flare.
AZA, azathioprine; BPLD, blood pressure lowering drug; GC, glucocorticoid; IS, immunosuppressant; CY, cyclophosphamide; MMF, mycophenolate mofetil; RTX, rituximab.